Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production

NCT03063645 | Completed Phase 1 FDA Drug

• 1 other identifier: AC-17-014_BE
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

To compare serum ketone body (i.e., total ketones, β hydroxybutyrate, and estimate of acetoacetate) levels after single dose administration of AC-1202 and 2 doses of AC-SD-01.

Conditions

Healthy

Keywords

Healthy volunteer; AC-1202; AC-SD-01; Pharacokinetic; ketone body

Outcome Measures

Primary Outcomes (21)

• total ketones AUC0-t

  The area under the concentration-time curve, from time 0 to the last observed non-zero concentration, as calculated by the linear trapezoidal method.

  0-24 hrs

• total ketones AUC0-inf

  The area under the concentration-time curve from time 0 extrapolated to infinity. AUC0-inf is calculated as the sum of AUC0-t plus the ratio of the last measurable serum concentration to the elimination rate constant.

  0-24 hrs

• total ketones AUC%extap

  Percent of AUC0-inf extrapolated, represented as (1 - AUC0-t/AUC0-inf)\*100

  0-24 hrs

• total ketones Cmax

  Maximum observed concentration

  0-24 hrs

• total ketones Kel

  Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the serum concentration versus time curve. The parameter will be calculated by linear least-squares regression analysis using the maximum number of points in the terminal log-linear phase (e.g., there or more non-zero serum concentrations)

  0-24 hrs

• total ketones T 1/2

  Apparent first-order terminal elimination half-life will be calculated as 0.693/Kel

  0-24 hrs

• total ketones Tmax

  Time to reach Cmax. If the value occurs at more than one time points, Tmax is defined as the first time point with this value

  0-24 hrs

• β hydroxybutyrate AUC0-t

  The area under the concentration-time curve, from time 0 to the last observed non-zero concentration, as calculated by the linear trapezoidal method.

  0-24 hrs

• β hydroxybutyrate AUC0-inf

  The area under the concentration time curve from time 0 extrapolated to infinity. AUC0inf is calculated as the sum of AUC0t plus the ratio of the last measurable serum concentration to the elimination rate constant.

  0-24 hrs

• β hydroxybutyrate AUC%extap

  Percent of AUC0-inf extrapolated, represented as (1 AUC0t/ AUC0inf)\* 100

  0-24 hrs

• β hydroxybutyrate Cmax

  Maximum observed concentration

  0-24 hrs

• β hydroxybutyrate Kel

  Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the serum concentration versus time curve. The parameter will be calculated by linear least-squares regression analysis using the maximum number of points in the terminal log-linear phase (e.g., three or more nonzero serum concentrations)

  0-24 hrs

• β hydroxybutyrate T 1/2

  Apparent first-order terminal elimination half-life will be calculated as 0.693/Kel

  0-24 hrs

• β hydroxybutyrate Tmax

  Time to reach Cmax. If the value occurs at more than one time point, Tmax is defined as the first time point with this value

  0-24 hrs

• estimate of acetoacetate AUC0-t

  Difference between total ketones AUC0-t and total β hydroxybutyrate AUC0-t

  0-24 hrs

• estimate of acetoacetate AUC0-inf

  Difference between total ketones AUC0-inf and total β hydroxybutyrate AUC0-inf

  0-24 hrs

• estimate of acetoacetate AUC%extap

  Difference between total ketones AUC%extap and total β hydroxybutyrate AUC%extap

  0-24 hrs

• estimate of acetoacetate Cmax

  Difference between total ketones Cmax and total β hydroxybutyrate Cmax

  0-24 hrs

• estimate of acetoacetate Kel

  Difference between total ketones Kel and total β hydroxybutyrate Kel

  0-24 hrs

• estimate of acetoacetate T 1/2

  Difference between total ketones T 1/2 and total β hydroxybutyrate T 1/2

  0-24 hrs

• estimate of acetoacetate Tmax

  Difference between total ketones Tmax and total β hydroxybutyrate Tmax

  0-24 hrs

Study Arms (3)

Group ABC

EXPERIMENTAL

AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)

Drug: AC-1202; Drug: AC-SD-01 (50 g); Drug: AC-SD-01 (75 g)

Group BCA

EXPERIMENTAL

AC-SD-01 (50g), AC-SD-01 (75g), AC-1202

Drug: AC-1202; Drug: AC-SD-01 (50 g); Drug: AC-SD-01 (75 g)

Group CAB

EXPERIMENTAL

AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)

Drug: AC-1202; Drug: AC-SD-01 (50 g); Drug: AC-SD-01 (75 g)

Interventions

AC-1202 DRUG

60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1

Group ABC; Group BCA; Group CAB

AC-SD-01 (50 g) DRUG

50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

Group ABC; Group BCA; Group CAB

AC-SD-01 (75 g) DRUG

75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1

Group ABC; Group BCA; Group CAB

Eligibility Criteria

• Age: 19 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy, adult, male 19-55 years of age, inclusive, at screening.
• Continuous non smoker who has not used nicotine containing products for at least 3 months prior to Day -1 of Period 1 and throughout the study.
• Body mass index (BMI) ≥ 20.0 and ≤ 30.0 kg/m2 at screening.
• Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. At screening, subjects must have alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) \< the upper limit of normal and triglyceride levels must be \< 250 mg/dL.
• A non vasectomized subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to Day -1 of Period 1. A subject who has been vasectomized less than 4 months prior to Day -1 of Period 1 must follow the same restrictions as a non vasectomized male).
• Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

You may not qualify if:

• Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
• History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.
• History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
• History or presence of alcoholism or drug abuse within the past 2 years prior to Day -1 of Period 1.
• History or presence of galactosemia or hypersensitivity or idiosyncratic reaction to the study drugs, related compounds, milk, palm or coconut oil, or soy.
• History or presence of diverticular disease, ulcers, inflammatory bowel disease or recurrent diarrhea or gout.
• Positive urine drug or alcohol results at screening or check in.
• Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
• Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
• Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
• QTcF interval is \> 460 msec or subject has ECG findings deemed abnormal with clinical significance by the PI or designee at screening.
• Estimated creatinine clearance ≤ 80 mL/min at screening.
• Unable to refrain from or anticipates the use of any drug, including prescription and non prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to Day -1 of Period 1 and throughout the study. Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study.
• Has been on a diet incompatible with the on study diet, in the opinion of the PI or designee, within the 28 days prior to Day -1 of Period 1 and throughout the study.
• Is lactose intolerant.

Sponsors & Collaborators

• Cerecin: lead
• Celerion: collaborator

Study Sites (1)

Celerion

Lincoln, Nebraska, 68502, United States

Location

MeSH Terms

Interventions

AC-1202

Study Officials

• Charles Tomek, MD

  Celerion

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: 16 healthy subjects enrolled, each subject will receive 1 dose of each treatment, with a 2 day washout in between.

Study Record Dates

• First Submitted: February 21, 2017
• First Posted: February 24, 2017
• Study Start: March 11, 2017
• Primary Completion: April 7, 2017
• Study Completion: May 5, 2017
• Last Updated: June 27, 2017

Record last verified: 2017-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)